L. Rivoltini

M. Salgaller, F. Marincola, L. Rivoltini, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Identification of a Mutated Receptor-Like Protein Tyrosine Phosphatase κ as a Novel, Class II HLA-Restricted Melanoma Antigen1

P. Robbins, G. Parmiani, C. Castelli, 2003, The Journal of Immunology.

Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies

P. Allavena, M. Rodolfo, C. Castelli, 2014, Cancer Immunology, Immunotherapy.

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010"

M. Hendrix, K. Flaherty, P. Ascierto, 2011, Journal of Translational Medicine.

Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

E. Petricoin, L. Liotta, F. Marincola, 2009, Journal of Translational Medicine.

Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

L. Mariani, G. Parmiani, C. Castelli, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vaccination: role in metastatic melanoma

A. Marrari, G. Parmiani, M. Santinami, 2006, Expert review of anticancer therapy.

Immunotherapy of melanoma.

A. Anichini, G. Parmiani, M. Santinami, 2003, Seminars in cancer biology.

Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction

P. Dalerba, A. Anichini, G. Parmiani, 2002, Immunological reviews.

Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer

M. Rodolfo, C. Castelli, L. Rivoltini, 2016, Vaccines.

The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.

P. Dalerba, S. Andreola, G. Parmiani, 2003, Cancer research.

Promoter methylation of aminopeptidase N/CD13 in malignant melanoma.

B. Seliger, K. Ikenberg, P. Wild, 2012, Carcinogenesis.

Spheres of influence in cancer stem cell biology.

L. Mariani, C. Castelli, L. Rivoltini, 2011, The Journal of investigative dermatology.

Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.

M. Salgaller, Y. Kawakami, F. Marincola, 1995, Cancer research.

HLA Associations in the Antitumor Response Against Malignant Melanoma

F. Marincola, D. Venzon, D. White, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.

T. Di Pucchio, P. Marchetti, E. Bonmassar, 2006, Cancer research.

NK Cell-Derived Exosomes Immune Surveillance Properties of Human

A. Molinari, F. Podo, F. Spadaro, 2012 .

microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response

M. Dugo, A. Gloghini, A. Maurichi, 2016, Genes.

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

C. Lanzi, P. Perego, G. Cassinelli, 2011, Neoplasia.

Potent Phagocytic Activity Discriminates Metastatic and Primary Human Malignant Melanomas: A Key Role of Ezrin

P. Matarrese, F. Lozupone, G. Parmiani, 2003, Laboratory Investigation.

Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg)

S. Buti, C. Caminiti, R. Passalacqua, 2015, Targeted Oncology.

Melanoma immunology: past, present and future

G. Parmiani, M. Santinami, C. Castelli, 2007, Current opinion in oncology.

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

L. Rivoltini, P. Filipazzi, V. Huber, 2012, Cancer Immunology, Immunotherapy.

Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b

Paola Frati, Viviana Vallacchi, Elisabetta Vergani, 2015, Oncotarget.

Genetic layout of melanoma lesions associates to BRAF/MEK-targeted therapy resistance and to transcriptional profiles.

G. Pruneri, M. Del Vecchio, L. De Cecco, 2022, The Journal of investigative dermatology.

Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells.

M. Colombo, P. Dalerba, S. Andreola, 2005, Cancer research.

Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients

D. Chaussabel, D. Bedognetti, L. De Cecco, 2021, Clinical and translational medicine.

Heat Shock Proteins and Their Use as Anticancer Vaccines

V. Mazzaferro, A. Testori, P. Srivastava, 2004, Clinical Cancer Research.

Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.

R. Kiessling, G. Parmiani, C. Castelli, 2001, Cancer research.

Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis

A. Necker, C. Giachino, G. Robustelli della Cuna, 2002, Melanoma research.

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.

S. Rosenberg, S. Topalian, P. Robbins, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.

L. De Cecco, S. Canevari, B. Vergani, 2014, Cancer research.

Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells.

M. Colombo, N. Cascinelli, A. Cattelan, 1999, Human gene therapy.

T-cell recognition of melanoma antigens and its therapeutic applications

G. Parmiani, C. Castelli, L. Rivoltini, 1997, International journal of clinical & laboratory research.

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.

M. Colombo, N. Cascinelli, M. Maio, 1996, Human gene therapy.

T-cell Receptor Repertoire in Matched MARTi Peptide-. stimulated Peripheral Blood Lymphocytes and Tumor-infiltrating Lymphocytes

M. Nishimura, L. Rivoltini, D. Cole, 2006 .

T cell response to tumor antigens and its therapeutic use in cancer patients.

P. Dalerba, G. Parmiani, C. Castelli, 2001, Advances in experimental medicine and biology.

T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.

M. Nishimura, L. Rivoltini, D. Cole, 1997, Cancer research.

Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope.

S. Rosenberg, M. Nishimura, S. Topalian, 1994, Cancer research.

Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.

G. Parmiani, F. Ravagnani, C. Castelli, 1999, Journal of immunology.

Melanoma Antigens Derived from Tyrosinase-Related Protein-2 Novel HLA-Cw 8-Restricted T Cell Epitopes

G. Parmiani, F. Ravagnani, C. Castelli, 1999 .

A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.

G. Parmiani, C. Castelli, L. Rivoltini, 1999, Cancer research.

Antigenic Peptide Immunodominant Melan-A/MART-1 HLA-A*0201-Restricted CTL Specific for the Diversity of the Fine Specificity Displayed by

P. Romero, D. Valmori, F. Jotereau, 1998 .

T‐cell recognition of melanoma‐associated antigens

G. Parmiani, C. Castelli, L. Rivoltini, 2000 .

Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response

V. Chiarion-Sileni, M. Maio, B. Vergani, 2013, Cancer Immunology, Immunotherapy.

Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide

P. Romero, G. Parmiani, L. Rivoltini, 2007, Cancer Immunology, Immunotherapy.

Interferon‐activated neutrophils store a TNF‐related apoptosis‐inducing ligand (TRAIL/Apo‐2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators

A. Mantovani, G. Peri, F. Calzetti, 2006, Journal of leukocyte biology.

Selective purging by human interleukin‐2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells

G. Parmiani, S. Siena, C. Gambacorti-Passerini, 1991, British journal of haematology.

In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.

G. Parmiani, C. Gambacorti-Passerini, R. Molinari, 1990, Cancer research.

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types

T. Negri, S. Pilotti, S. Stacchiotti, 2018, Journal of immunology research.

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

G. Parmiani, C. Castelli, L. Rivoltini, 2010, The Journal of Immunology.

Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides

L. Mariani, V. Chiarion-Sileni, M. Maio, 2012, Clinical Cancer Research.

Murine granulocytes control human tumor growth in SCID mice

F. Lozupone, F. Belardelli, G. Parmiani, 2000, International journal of cancer.

Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells1

Jonathan J. Lewis, V. Mazzaferro, P. Srivastava, 2003, The Journal of Immunology.

Carcinoma-Specific T Cells Expansion of Melanoma- and Colon Mediates In Vitro Activation and In Vivo Human Tumor-Derived Heat Shock Protein 96

Jonathan J. Lewis, V. Mazzaferro, P. Srivastava, 2003 .

Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

S. Rosenberg, S. Topalian, A. Mixon, 1995, Cancer research.

Modulation of multidrug resistance by verapamil or mdr1 anti‐sense oligodeoxynucleotide does not change the high susceptibility to lymphokine‐activated killers in mdr‐resistant human carcinoma (LoVo) line

T. Tsuruo, M. Colombo, R. Supino, 1990, International journal of cancer.

Vaccination of patients with solid tumours.

G. Parmiani, C. Castelli, L. Rivoltini, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.

G. Zupi, F. Zunino, P. Perego, 2005, European journal of cancer.

Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?

G. Parmiani, R. Valdagni, M. Santinami, 2009, Cancer Immunology, Immunotherapy.

Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice

F. Lozupone, F. Belardelli, G. Parmiani, 2003, European journal of immunology.

Monitoring the frequency and function of regulatory T cells and summary of the approaches currently used to inhibit regulatory T cells in cancer patients.

C. Castelli, L. Rivoltini, C. Camisaschi, 2014, Methods in molecular biology.

Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.

M. Colombo, G. Parmiani, C. Castelli, 1998, Journal of immunology.

Mechanisms for Tumor Killing and Use Fas / Fas Ligand-Independent CTL Clones Resist Fas Ligand-Induced Apoptosis + and CD 8 + Human Melanoma-Reactive CD 4

M. Colombo, G. Parmiani, C. Castelli, 1998 .

Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.

C. Farina, G. Nicolini, T. Wölfel, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells

S. Rosenberg, S. Topalian, R. Hartzman, 1994, International journal of cancer.

Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

K. Sakaguchi, E. Appella, S. Rosenberg, 1995, Journal of immunology.

Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial.

A. Eggermont, P. Romero, C. Scheibenbogen, 2000, Journal of immunological methods.

Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype

G. Parmiani, C. Gambacorti-Passerini, L. Rivoltini, 2005, Cancer Immunology, Immunotherapy.

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

D. Hicklin, S. Ferrone, G. Parmiani, 1998, The Journal of clinical investigation.

Exploiting liver immunity for the prevention of hepatic metastases.

V. Mazzaferro, L. Rivoltini, 2010, Journal of hepatology.

Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1993, Cancer Immunology, Immunotherapy.

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

G. Broggi, A. Silvani, A. Salmaggi, 1994, Cancer Immunology, Immunotherapy.

Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells

A. Silvani, G. Parmiani, L. Rivoltini, 1993, Cancer Immunology, Immunotherapy.

Differences between in Vivoand in Vitro Activation of Cancer Patient Lymphocytes by Recombinant Inter leukin 2 : Possible Role for Lymphokine-activated Killer Cell Infusion in the in F / vo-induccd Activation 1

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 2006 .

Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1989, Cancer research.

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.

P. Duray, M. Herlyn, J. Cormier, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.

F. Marincola, G. Parmiani, C. Castelli, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

In vitro anti‐tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5

M. Colombo, A. Santoro, K. Takatsu, 1993, International journal of cancer.

Amino Acid Substitutions in the Melanoma Antigen Recognized by T Cell 1 Peptide Modulate Cytokine Responses in Melanoma-Specific T Cells

C. Geisler, J. Zeuthen, N. Odum, 2000, Journal of immunotherapy.

Altered peptide ligands of tumor T-cell epitopes: implications for more effective vaccine therapy in human neoplasia

G. Parmiani, L. Rivoltini, M. Carrabba, 2003 .

Don't run before you can walk

A. Marrari, R. Valdagni, C. Castelli, 2012, Nature Reviews Urology.

Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers

V. Mazzaferro, L. Bergamaschi, C. Castelli, 2022, Gut.

Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.

G. Parmiani, C. Castelli, L. Rivoltini, 2006, Cancer research.

Human Plasmacytoid Dendritic Cells Interact with gp96 via CD91 and Regulate Inflammatory Responses1

A. Villa, G. Parmiani, P. Della Mina, 2008, The Journal of Immunology.

Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.

B. Vergani, A. Villa, M. Santinami, 2014, The Journal of investigative dermatology.

NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients

D. Nonaka, G. Parmiani, A. Piris, 2007, Clinical Cancer Research.

NKG 2 D-Mediated AntitumorActivity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated fromMelanoma Patients

D. Nonaka, G. Parmiani, A. Piris, 2007 .

Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.

B. Czerniecki, S. Rosenberg, L. Rivoltini, 1997, Journal of immunology.

Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients

G. Parmiani, C. Castelli, L. Rivoltini, 2005, Clinical Cancer Research.

Inflammatory Responses with gp96 via CD91 and Regulate Human Plasmacytoid Dendritic Cells Interact

A. Villa, G. Parmiani, C. Castelli, 2008 .

Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes.

A. Carè, M. Colombo, G. Parmiani, 1993, Blood.

myb That Express c-Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines Antisense myb Inhibition of Proliferation by c-Updated Version

M. Colombo, B. Calabretta, G. Parmiani, 2006 .

Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.

P. Dalerba, L. Old, C. Lombardo, 2003, Cancer research.

Cancer Therapy : Clinical Frequency of Circulating Tregs with Demethylated FOXP 3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

C. Punt, P. Coulie, G. Adema, 2011 .

Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

C. Punt, P. Coulie, G. Adema, 2010, Clinical Cancer Research.

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer

S. Manoukian, F. D. De Braud, G. Mariani, 2018, Scientific Reports.

Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.

F. Marincola, E. Appella, C. Geisler, 1998, Critical reviews in immunology.

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.

M. Colombo, G. Parmiani, M. Santinami, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

E. Thiel, H. Buhr, C. Scheibenbogen, 2000, Cancer research.

LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites

G. Parmiani, C. Castelli, L. Rivoltini, 2010, The Journal of Immunology.

OA14.06 Hyperprogressive Disease in Advanced Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

M. Colombo, G. Pruneri, M. Boeri, 2019, Journal of Thoracic Oncology.

Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.

A. Villa, G. Parmiani, S. Fais, 2006, Cancer research.

Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation1

G. Parmiani, C. Castelli, L. Rivoltini, 2008, The Journal of Immunology.

Cell Activation Deliver Costimulation Signal for Dendritic Molecules Expressed by Activated T Cells Human Lymphocyte Activation Gene-3 Parmiani and

G. Parmiani, C. Castelli, L. Rivoltini, 2008 .

Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes

A. Carè, M. Colombo, G. Parmiani, 1993 .

pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma

V. Mazzaferro, S. Carradori, C. Supuran, 2018, Oncoimmunology.

Chronic Effects of Subcutaneous Interleukin-2 Therapy on Soluble Interleukin-2 Receptors in Advanced Small Cell Lung Cancer

L. Rivoltini, F. Arienti, P. Bidoli, 1993, The International journal of biological markers.

Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.

F. Benvenuto, G. Merlini, C. Giachino, 2003, The Journal of investigative dermatology.

Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.

G. Parmiani, M. Maeurer, C. Castelli, 2003, Cancer research.

Optimized Analogues Altered Peptide Ligands : Role of MelanA / MART-1 T Cells by Melanoma-derived + Suboptimal Activation of CD 8 Updated Version

G. Parmiani, M. Maeurer, C. Castelli, 2003 .

CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.

A. Carbone, G. Parmiani, N. Lazar, 2008, Cancer research.

CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.

A. Carbone, G. Parmiani, N. Lazar, 2008, Cancer Research.

Antitumor activity of delimotecan against human metastatic melanoma: Pharmacokinetics and molecular determinants

M. Binaschi, C. Maggi, M. Bigioni, 2009, International journal of cancer.

Tumor-released microvesicles as vehicles of immunosuppression.

G. Parmiani, L. Rivoltini, P. Filipazzi, 2007, Cancer research.

Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration.

A. Caraceni, N. Cascinelli, L. Rivoltini, 1993, European journal of cancer.

Effect of Prolonged Subcutaneous Administration of Interleukin-2 on the Orcadian Rhythms of Cortisol and Beta-Endorphin in Advanced Small Cell Lung Cancer Patients

G. Parmiani, L. Rivoltini, S. Viviani, 1991, Tumori.

Cytokine-based gene therapy of human tumors. An overview.

M. Colombo, N. Cascinelli, J. Sulé-Suso, 1996, Folia biologica.

Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance

R. Supino, G. Parmiani, C. Gambacorti-Passerini, 1989, International journal of cancer.

A new Procedure for Large Scale Production and Freezing of Lymphokine Activated Killer (LAK) Cells to be used in Adoptive Immunotherapy of Cancer

N. Cascinelli, G. Parmiani, C. Gambacorti-Passerini, 1988, Tumori.

The high lysability by lak cells of colon‐carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM‐1, LFA‐3, NCA and a less‐differentiated phenotype

M. Colombo, G. Cattoretti, G. Parmiani, 1991, International journal of cancer.

T-cell recognition of melanoma-associated antigens.

G. Parmiani, C. Castelli, L. Rivoltini, 2000, Journal of cellular physiology.

Erratum: In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5 (Int. J. Cancer, 54, 8-15 (1993))

M. Colombo, A. Santoro, K. Takatsu, 1993 .

Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

V. Torri, Raghvendra Mall, G. Apolone, 2021, Cancer discovery.

ITOC2 – 038. Role of exosomes in immune suppression

V. Bollati, S. Canevari, M. Santinami, 2015 .

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

3D tumor explant as a novel platform to investigate therapeutic pathways and predictive biomarkers in cancer patients

M. Rodolfo, L. Rivoltini, V. Huber, 2022, Frontiers in Immunology.

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

J. Utikal, A. Hauschild, D. Schadendorf, 2016, ESMO Open.

Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.

S. Manoukian, S. Pilotti, A. Ferrari, 2009, The Journal of investigative dermatology.

DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress‐induced apoptosis

M. Pierotti, M. Daniotti, M. Rodolfo, 2005, International journal of cancer.

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

K. Sakaguchi, E. Appella, S. Rosenberg, 1994, The Journal of experimental medicine.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

F. Lozupone, A. Molinari, F. Belardelli, 2004, Journal of the National Cancer Institute.

Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients

L. Mariani, F. D. De Braud, M. Del Vecchio, 2021, Journal for ImmunoTherapy of Cancer.

Immunological Features of Melanoma: Clinical Implications in the Era of New Therapies

L. Rivoltini, A. Cova, P. Squarcina, 2021 .

The AURORA of a New Way to Value Myeloid Immunosuppression in Cancer.

L. Rivoltini, V. Huber, C. Vernieri, 2019, Cancer research.

A variant in FTO shows association with melanoma risk not due to BMI

Marko Hočevar, Florence Demenais, Kari Stefansson, 2013, Nature Genetics.

Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.

M. Colombo, B. Calabretta, G. Parmiani, 1991, Cancer research.

A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma

S. Manoukian, A. Ferrari, B. Pasini, 2014, BMC Medical Genetics.

Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility

Blair H. Smith, Jeffrey E. Lee, G. Abecasis, 2020, Nature Genetics.

Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

L. Mariani, P. Altevogt, V. Bollati, 2018, The Journal of clinical investigation.

Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity

D. Chaussabel, D. Bedognetti, L. De Cecco, 2020, bioRxiv.

Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)

F. Marincola, E. Appella, M. Nishimura, 1996, The Journal of experimental medicine.

Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review.

C. Porta, S. Bracarda, L. Rivoltini, 2019, Critical reviews in oncology/hematology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients

Massimo Spada, Veronica Huber, Licia Rivoltini, 2009, PloS one.

Tumour-released exosomes and their implications in cancer immunity

G. Parmiani, S. Fais, L. Rivoltini, 2008, Cell Death and Differentiation.

HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy

H. Vaudry, T. Frebourg, J. Leprince, 2010, Journal of immunotherapy.

Vaccination therapy in prostate cancer

A. Marrari, R. Salvioni, G. Parmiani, 2007, Cancer Immunology, Immunotherapy.

Potential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy

M. Campiglio, S. Ménard, A. Villa, 2012, Journal of cellular physiology.

BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients

M. Rodolfo, L. Rivoltini, V. Vallacchi, 2011 .

Tumor Exosomes and Their Impact on Immunity and Cancer Progression

L. Rivoltini, P. Filipazzi, V. Huber, 2013 .

Recent advances on the role of tumor exosomes in immunosuppression and disease progression.

Veronica Huber, Licia Rivoltini, Antonello Villa, 2012, Seminars in cancer biology.

Extracellular vesicles in anti-tumor immunity.

L. Bergamaschi, M. Rodolfo, C. Castelli, 2021, Seminars in cancer biology.

microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy

L. Bergamaschi, M. Rodolfo, C. Castelli, 2020, Frontiers in Immunology.

IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.

Giovanni Martinelli, Veronica Huber, Licia Rivoltini, 2004, Blood.

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology

F. Marincola, J. Malek, E. Wang, 2013, The Journal of investigative dermatology.

Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease

A. Gasbarrini, V. Mazzaferro, M. Pompili, 2018, Hepatology.

Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer

Alessandro Testori, Pramod K. Srivastava, Licia Rivoltini, 2004, Cancer Immunology, Immunotherapy.

Mechanisms of tumor immunotherapy, with a focus on thoracic cancers.

L. Rivoltini, V. Huber, S. Ferro, 2018, Journal of thoracic disease.

Cancer vaccines and active immunotherapy

R. Zappasodi, L. Rivoltini, P. Filipazzi, 2013 .

Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

F. Marincola, S. Rosenberg, J. Cormier, 1997, The cancer journal from Scientific American.

Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy

P. Casali, T. Negri, S. Pilotti, 2014, British Journal of Cancer.

Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation.

E. Tagliabue, T. Triulzi, C. Castelli, 2017, Seminars in cancer biology.

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

P. Ascierto, A. Testori, E. Simeone, 2012, The Lancet. Oncology.

Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.

L. Mariani, R. Miceli, A. Cavallo, 2016, International journal of radiation oncology, biology, physics.

Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?

F. Lozupone, G. Parmiani, S. Fais, 2005, Expert opinion on biological therapy.

Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells

B. Vergani, A. Villa, D. Giardiello, 2016, Stem cells.

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

V. Torri, A. Bardelli, M. Colombo, 2018, Clinical Cancer Research.

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol

C. Figdor, M. Middleton, P. Ottevanger, 2021, BMJ Open.

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors

P. Queirolo, M. Del Vecchio, M. Mandalà, 2019, Journal of Immunotherapy for Cancer.

Elisabetta Vergani, Veronica Huber, Licia Rivoltini, 2016, Clinical Cancer Research.

Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence

S. Cascinu, L. Porcu, L. Rivoltini, 2020, Cancers.

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting.

L. Zitvogel, F. D. De Braud, S. Cosimo, 2018, Cytokine & growth factor reviews.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

S. H. van der Burg, F. Marincola, A. Palucka, 2011, Clinical Cancer Research.

T cell responses against tumor associated antigens and prognosis in colorectal cancer patients

E. Thiel, C. Germer, H. Buhr, 2005, Journal of Translational Medicine.

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.

A Sette, F. Marincola, A. Sette, 1995, Journal of immunology.

Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).

E. Appella, C. Geisler, G. Parmiani, 1998, Cancer research.

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Francesco M Marincola, Licia Rivoltini, Piero Dalerba, 2002, Journal of the National Cancer Institute.

Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment.

L. De Cecco, P. Casali, T. Negri, 2017, The Journal of investigative dermatology.

New common variants affecting susceptibility to basal cell carcinoma

D. Gudbjartsson, A. Sigurdsson, T. Blondal, 2009, Nature Genetics.

Local Adoptive Immunotherapy of Advanced Head and Neck Tumors with Lak Cells and Interleukin-2

G. Parmiani, F. Ravagnani, L. Rivoltini, 1990, Tumori.

Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity

C. Castelli, L. Rivoltini, C. Camisaschi, 2014, Oncoimmunology.

Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients

S. Manoukian, L. De Cecco, M. Dugo, 2021, Genes.

Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study

M. Gariboldi, G. Apolone, P. Pasanisi, 2021, Cancer Prevention Research.

A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results

M. Gariboldi, G. Apolone, P. Pasanisi, 2019, Integrative cancer therapies.

Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage?

F. D. De Braud, G. Procopio, L. Rivoltini, 2020, Journal of clinical medicine.

Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.

L. Licitra, L. Locati, P. Bossi, 2018, Cancer treatment reviews.

Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.

G. Parmiani, S. Fais, E. Seregni, 2005, Gastroenterology.

Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1

F. Belardelli, G. Parmiani, L. Rivoltini, 2004, The Journal of Immunology.

Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.

Jonathan J. Lewis, L. Mariani, V. Mazzaferro, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts).

D. Bedognetti, D. Rinchai, G. Procopio, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report

P. Casali, T. Negri, S. Pilotti, 2015, BMC Cancer.

Induction of Both CD8+ and CD4+ T-Cell–Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1

M. Tartaglia, V. Zagonel, F. Belardelli, 2008, Clinical Cancer Research.

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report

P. Casali, T. Negri, S. Pilotti, 2015, BMC Cancer.

Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma

T. Negri, S. Pilotti, S. Stacchiotti, 2013, Journal of Translational Medicine.

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Yingdong Zhao, Holden Maecker, Sylvia Janetzki, 2008, Journal of Translational Medicine.

Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin‐2 and lymphokine activated killer cells. A pilot study

N. Cascinelli, M. Ammatuna, G. Parmiani, 1992, Melanoma research.

Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.

Jonathan J. Lewis, A. Testori, P. Queirolo, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

V a c c ination o f M etastatic M elanoma P atients W ith Autologous T umor-Derived H eat S hock P rotein g p96- Peptide C omplexes: C linical a nd I mmunologic F indings

Jonathan J. Lewis, A. Testori, P. Queirolo, 2002 .

T-cell response to unique and shared antigens and vaccination of cancer patients.

A. Anichini, G. Parmiani, C. Castelli, 2002, Cancer immunity.

Detection of mutated BRAFV600E variant in circulating DNA of stage III–IV melanoma patients

M. Pierotti, G. Parmiani, M. Daniotti, 2007, International journal of cancer.

Melanoma Cells Homing to the Brain: An In Vitro Model

C. Calatozzolo, A. Salmaggi, L. Rivoltini, 2015, BioMed research international.

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.

F. Marincola, E. Appella, M. Salgaller, 1996, Journal of immunology.

A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.

C. Porta, F. Braud, U. Giorgi, 2019, Journal of Clinical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

pH‐dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity

F. Lozupone, F. Podo, A. Villa, 2010, International journal of cancer.

Biologic agents as modifiers of chemotherapeutic effects

L. Rivoltini, Giorgio Parmiani, 1991, Current opinion in oncology.

miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

M. Dugo, B. Vergani, M. Ferrarini, 2020, Cell Communication and Signaling.

Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.

P. Romero, D. Valmori, F. Jotereau, 1998, Journal of immunology.

Multipeptide vaccination in cancer patients

A. Marrari, G. Parmiani, R. Valdagni, 2009, Expert opinion on biological therapy.

Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients

M. Maio, G. Parmiani, C. Castelli, 1998, European journal of immunology.

Nanobiotechnology and Immunotherapy: Two Powerful and Cooperative Allies against Cancer

M. Eccles, M. Di Nicola, L. Rivoltini, 2021, Cancers.

Cytokines in cancer therapy.

G. Parmiani, L. Rivoltini, M. Carrabba, 2000, Immunology letters.

Selective Histocompatibility Leukocyte Antigen (Hla)-A2 Loss Caused by Aberrant Pre-mRNA Splicing in 624mel28 Melanoma Cells

F. Marincola, S. Ferrone, G. Parmiani, 1999, The Journal of experimental medicine.

Microenvironment and Immunology Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-In fi ltrating T Lymphocytes

R. Canese, G. Parmiani, S. Fais, 2012 .

Class I HLA Folding and Antigen Presentation in β2-Microglobulin-Defective Daudi Cells1

Elisa Lo Monaco, A. Martayan, P. Giacomini, 2009, The Journal of Immunology.

Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface.

R. Kiessling, C. Castelli, L. Rivoltini, 2001, Blood.

Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes

F. Fazio, L. Gianolli, P. Coulie, 2013, International journal of cancer.

CEA and NCA Expressed by Colon Carcinoma Cells Affect their Interaction with and Lysability by Activated Lymphocytes

G. Cattoretti, G. Parmiani, A. Mastroianni, 1992, The International journal of biological markers.

Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.

G. Parmiani, C. Gambacorti-Passerini, L. Rivoltini, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Universal and Stemness-Related Tumor Antigens: Potential Use in Cancer Immunotherapy

A. Marrari, G. Parmiani, C. Castelli, 2007, Clinical Cancer Research.

Heat shock proteins gp96 as immunogens in cancer patients

G. Parmiani, C. Castelli, L. Rivoltini, 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.

A. Anichini, G. Parmiani, M. Maeurer, 1996, Journal of immunology.

More insights into the immunosuppressive potential of tumor exosomes

S. Fais, L. Rivoltini, P. Filipazzi, 2008, Journal of Translational Medicine.

Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy

M. Rodolfo, C. Castelli, L. Rivoltini, 2018, Virchows Archiv.

Immune Surveillance Properties of Human NK Cell-Derived Exosomes

A. Molinari, F. Podo, F. Spadaro, 2012, The Journal of Immunology.

Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells.

Licia Rivoltini, Massimo Gentile, Stefano Fais, 2006, Cancer research.

Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals

N. Zaffaroni, P. Perego, N. Carenini, 2014, Oncotarget.

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

K. Sakaguchi, E. Appella, S. Rosenberg, 1994, The Journal of experimental medicine.

Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells.

L. Mariani, M. Daidone, A. Villa, 2010, The Journal of investigative dermatology.

A novel computational method for automatic segmentation, quantification and comparative analysis of immunohistochemically labeled tissue sections

Elena Casiraghi, Marco Frasca, Veronica Huber, 2018, BMC Bioinformatics.

The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors

S. Fais, L. Rivoltini, A. De Milito, 2013, Oncoimmunology.

Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment

M. Rodolfo, C. Castelli, L. Rivoltini, 2014, Expert review of molecular diagnostics.

Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells

S. Pattingre, P. Codogno, F. Lozupone, 2010, Cell Death and Disease.

Proton dynamics in cancer

R. Gatenby, J. Pouysségur, S. Fais, 2010, Journal of Translational Medicine.

Development of a Molecular Blood-Based Immune Signature Classifier as Biomarker for Risks Assessment in Lung Cancer Screening

U. Pastorino, O. Fortunato, M. Boeri, 2022, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Fasting-mimicking diet plus chemotherapy in breast cancer treatment

L. Rivoltini, C. Vernieri, F. Ligorio, 2020, Nature Communications.

Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center

G. Apolone, G. Galli, M. Duca, 2022, Therapeutic advances in medical oncology.

The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer

S. Manoukian, F. D. De Braud, G. Mariani, 2018, Scientific Reports.

Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

G. Parmiani, P. Collini, R. Luksch, 2018, BMC Cancer.

Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer

F. D. De Braud, G. Pruneri, A. Belfiore, 2020, Cancers.

CCN3 Promotes Melanoma Progression by Regulating Integrin Expression, Adhesion and Apoptosis Induced by Cytotoxic Drugs

M. Daniotti, B. Perbal, M. Rodolfo, 2010 .

May impaired response to PD-1 blockers of high serum PD-1 patients be related to immune complexes?

B. Vergani, M. Garassino, L. Rivoltini, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes

M. Colombo, M. Del Vecchio, C. Lombardo, 2001, Cancer Immunology, Immunotherapy.

Commentarydynamics in cancer

R. Gatenby, J. Pouysségur, S. Fais, 2010 .

Low baseline neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict increased overall survival in locally recurrent rectal cancer despite R1 margins.

M. Milione, L. Battaglia, L. Rivoltini, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.

F. Lozupone, F. Belardelli, G. Parmiani, 2004, Cancer research.

miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

M. Del Vecchio, M. Dugo, B. Vergani, 2020, Cell Communication and Signaling.

Tumor-Derived Exosomes as Dendritic Cell Modulators

G. Parmiani, L. Rivoltini, P. Filipazzi, 2009 .

A novel computational method for automatic segmentation, quantification and comparative analysis of immunohistochemically labeled tissue sections

E. Casiraghi, B. Vergani, A. Villa, 2018, BMC Bioinformatics.

MIAQuant, a novel system for automatic segmentation, measurement, and localization comparison of different biomarkers from serialized histological slices

Elena Casiraghi, Veronica Huber, Mara Cossa, 2017, European journal of histochemistry : EJH.

Melanoma and other skin tumors

Y. S. Kim, Su Jin Lee, J. Utikal, 2012 .